MT-UAVIONIX
uAvionix Corporation today announced it achieved DoD AIMS Mk XIIB certification of its first Identification Friend or Foe (IFF) transponder, the RT-2087/ZPX-B . With this certification, ZPX-B becomes the world’s smallest, certified micro-IFF transponder, reducing Size, Weight, and Power Consumption (SWaP) characteristics of typical IFF transponders by more than 90%, and at less than half the size, one-third the weight, and one fourth the power consumption of other Unmanned Aircraft Systems (UAS) targeted IFF solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005976/en/
The certification, issued by the Department of Defense (DoD) Air Traffic Control Radar Beacon System Identification Friend or Foe Program Office (AIMS PO), attests to its IFF capability and its interoperability with military equipment fielded by NATO and its allied countries. Incorporation of IFF technology into small, tactical, and attritable platforms allows them full participation into the cross-troop, cross-service branch, and cross-nation collaboration and situational awareness that prevents fratricide.
The ZPX-B enables IFF capability for small and tactical Group 1-4 UAS, thanks to its record-breaking SWaP at 3.3 in3 , 60 grams, and power consumption of only 3.5 Watts. Transmitting at 54dBm, ZPX-B provides civil transponder modes A, C, S, and ADS-B Out, as well as military modes 1, 2, 3, and 5 Levels 1 and 2 – all individually configurable. ADS-B In functionality provides situational awareness and Detect and Avoid (DAA) capabilities to the host platform. Crypto compatibility complies with AIMS 04-900A Option B, which includes the KIV-77 and KIV-79.
Passive IFF Reception for Situational Awareness
In addition to the ZPX-B, uAvionix introduces the ZPX-R, a passive ADS-B and Mode 5 Level 2 receiver for ground-based, shipborne, or airborne reception for situational awareness and DAA capability. Mode 5 Level 2 encrypted squitters enable situational awareness in areas where Mode 5 interrogators are absent, increasing the scalability of deployment. ZPX-R can provide data in multiple formats, including Open Mission Systems (OMS) for incorporation into tactical displays or ACAS Xu or similar DAA processors.
Unclassified Integration, Testing, and Demonstration with Crypto Emulation
For military programs or OEMs looking to integrate a micro-IFF into their platforms, ZPX-B incorporates an internal crypto-emulator that enables development and test independent of COMSEC-controlled equipment subject to onerous handling requirements.
For more information on the uAvionix line of defense products, including IFF transponders, receivers, GPS, and crypto emulators, visit https://uavionix.com/defense/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005976/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom